Clinical trial · no report yet · Phase not applicable
NCT06610344
BHB & CAR-T for Lymphomas
- NCT06610344 ↗
- Recruiting
- Abramson Cancer Center at Penn Medicine
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Preliminary Investigation of β-hydroxybutyrate Supplementation for Lymphoma Patients Receiving Anti-CD19 CAR T-cells
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Large B-cell Lymphoma
- Interventions
- R-1,3-Butanediol
- Arms
- R-1,3-Butanediol · Experimental
- Enrollment
- 5 (estimated)
- Primary outcomes
- Safety and tolerability
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Start
- Jan 7, 2025
- Primary completion
- Sep 15, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06610344 · updated Feb 23, 2026